アジア太平洋地域の医薬品アイソレータ市場 – 業界動向と2029年までの予測

アジア太平洋地域の医薬品アイソレータ市場の分析と洞察

製薬アイソレータは、製薬業界で汚染のないバリアシステムとして使用されています。微生物学的検査、細胞療法処理、先進医薬品（ATMP）製造、滅菌注射剤の計量、包装、配送は、製薬アイソレータのほんの一例です。製薬アイソレータの使用は、発展途上国と先進国の製薬市場の継続的な成長と、革新的な治療法を生み出すための研究開発費の増加によって促進されています。先進的な医療用絶縁体と製薬業界の要件により、大手メーカーは医療用絶縁体業界を成長させています。予測期間中、有害化合物の使用の増加、非準拠のコストの増加、研究室の増加は、製薬アイソレータ市場を牽引する重要な要因です。

しかし、ほとんどの専門家は、規制当局がもはや医薬品絶縁体の開発などの画期的な進歩の妨げにはならないという意見には反対している。

Data Bridge Market Research は、アジア太平洋地域の医薬品アイソレータ市場は、予測期間中に 15.7% の CAGR で成長し、2029 年までに 12 億 2,938 万米ドルに達すると予測しています。医薬品アイソレータの世界的な需要が急増しているため、タイプは市場で最大のタイプ セグメントを占めています。この市場レポートでは、価格分析、特許分析、技術の進歩についても詳細に取り上げています。

アジア太平洋地域の医薬品アイソレータ市場の定義

隔離の概念は、環境を保護しながら、プロセスをオペレータから、またはオペレータをプロセスから保護します。封じ込めの鍵は、最小限の暴露です。暴露範囲を化合物に設定された危険レベル以下に制御することにより、オペレータと環境が適切に保護されます。したがって、製品が保護され、重要な規制問題に対処します。製薬アイソレータは、無菌充填および有毒プロセスのために製薬環境で使用される密閉された細菌囲いです。完全に無菌のメインアイソレータで構成され、壁の1つに配置された肩の高さの手袋を使用して製品が取り扱われ、保管または梱包されます。製薬アイソレータは、製薬プロセスの制御と封じ込めを可能にします。製薬アイソレータの動作に必要な条件は、無菌環境であり、生存可能な微生物が存在しないことです。製薬アイソレータは、製造エリアと無菌環境が別々の位置に配置されることを保証します。製薬業界のアイソレータは、無菌環境の製薬業界のクリーンルームと比較して、費用対効果が高く効率的です。アイソレーターやアクセス制限バリアに求められるさまざまな認証基準に適応することで、微生物および医薬品製造プロセス中に制御された雰囲気を作り出します。同時に、製品、オペレーター、環境の保護を保証します。

医薬品アイソレータの豊富な用途は、生産と管理の目的によって異なります。固体、半固体、または粉末の医薬品の取り扱い、転送、梱包、溶液や輸液の取り扱いとファイリングに使用されます。医薬品アイソレータは、無菌試験、組織または生物学的生産システムまたは病原性サンプルの無菌取り扱いなどに適用されます。医薬品や医薬品の生産と管理に使用できます。製薬およびバイオテクノロジー業界全体でのアイソレータの需要の急増、低い運用コスト、医薬品の生産における無菌状態の高度な維持、およびバイオ医薬品業界の需要の増加は、予測期間中に市場の成長を促進すると予想される要因です。

また、市場プレーヤーによる戦略的取り組み、医薬品アイソレータの技術的進歩、高度な無菌性の保証、医療インフラへの投資の増加により、医薬品アイソレータ市場の成長が促進されます。

アジア太平洋地域の医薬品アイソレータ市場の動向

このセクションでは、市場の推進要因、利点、機会、制約、課題について理解します。これらについては、以下で詳しく説明します。    

ドライバー

急成長する製薬業界における医薬品アイソレーターの需要増加

医薬品アイソレータは、医薬品の手順または活動をオペレータおよび隣接する環境から分離する分離装置です。次のようなさまざまな目的で使用されます。

• 活動または手順に対して分類された無菌環境を提供し、作業者および隣接環境から発生する微生物および非微生物汚染から保護することを製品保護と呼びます。
• 他の製品や手順によって、また同時に、あるいは以前の操作中に生成された汚染から製品を保護します。これは、方法生成汚染または交差汚染に対する保護手段と呼ばれます。

製造ユニットにおける汚染問題が増加しており、アイソレータにより、汚染と汚染除去に役立つ医薬品アイソレータの需要が生まれています。

• 医薬品アイソレータの低い運用コスト

密閉されたエンクロージャは、適格な管理環境の内部を構成し、周囲の状況に合わせて気密性を確保します。アイソレータの用途は、医薬品製造の研究開発から、特に微生物学的品質管理のための実験室での使用まで多岐にわたります。一方、医薬品の無菌製造には、極めて高い清浄度基準があり、無菌製造のためのほぼ完全な粒子および細菌のない環境が求められます。

製薬業界の成長と製品範囲の拡大により、ますます多くのメーカーとサプライヤーがクリーンルーム技術の最新の追加技術への投資について検討する必要が生じています。

Aseptic processing of the pharmaceutical drugs is the major factor need to be included in good manufacturing practices meeting the government regulations. The high cost of the maintenance of the aseptic condition by clean room technology which is around 62% higher than the pharmaceutical isolators, shifting the manufacturers to acquire isolator’s technology and constraining the overall manufacturing cost of the pharmaceutical products.

Restraint

Stringent governmental regulations

Active Pharmaceutical Ingredients (API) and intermediates for pharmaceutical use (for instance biological, radiopharmaceutical, and pharmaceutical) and those used to production drugs for clinical trials are regulated under the Divisions 1A and 2, Part C of the Food and Drug Regulations.

• Division 1A, Part C of the Food and Drug Regulations describes activities for which Good Manufacturing Practices (GMP) compliance is required and must be demonstrated prior to the issuance of an API establishment license (EL).
• Division 2, Part C of the Food and Drug Regulations defines the requirements for the GMP of APIs and API intermediates, which are interpreted in the present guidance document.

Due to this strict regulation by the government that has to be followed for the production by the Good Manufacturing Practices (GMP) Guidelines for Active Pharmaceutical Ingredients (API) - (GUI-0104) which constraining the market growth rate.

Opportunity

• Strategic initiatives by market players

The rise in the pharmaceutical isolators market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The rising demand for pharmaceuticals is significantly increasing the demand for excipient and to cope with this demand companies are building new manufacturing sites among other strategic initiatives.

These strategic initiatives such as product launches, agreement and business expansion by the major market player will boost the pharmaceutical isolators market growth and is expected to act as an opportunity for the Asia-Pacific medical display market.

Challenge

Lack of skilled expertise

The shortage of skilled expertise would challenge the pace of recovery and growth in one place. Often, the people who are unemployed in one place have skills that are in short supply elsewhere. Moreover, rapid technological advancement in this field also leads to lack of expertise.

Lack of skilled professionals while handling the pharmaceutical isolators poses a major challenge while selecting and developing the pharmaceutical isolators. The data by the Phys.org 2003 mentions the medical display industries are facing a shortage of workers due to increase demand of pharmaceutical isolators in Asia-Pacific region and severe scarcity of micro chips used in LED and LCD display, which increases the price lead times of LCD production.

As skill demands are too high, it has manifested as a challenge to retain and manage skill-specified professionals. Moreover, technological advancement is another aspect that leads to the increased demand for skilled professionals. Neurologists report significant unmet supportive care needs and barriers in their centers with only a small minority rating themselves as competently providing supportive care. There is an urgent need for education of neurologists and professionals for treatment of dementia and procuring available supportive care resources. Lack of trained and experienced professionals and persistent skill gaps limit the employability prospects and access to quality jobs. It is therefore apparent that availability of professionals equipped with adequate skills is expected to challenge the market growth.

Post-COVID-19 Impact on Asia-Pacific Pharmaceutical Isolator Market

The COVID-19 pandemic has become the world's most serious threat. It wreaked havoc in many stores and businesses around the world. The pandemic, on the other hand, has provided many opportunities for pharmaceutical and biopharmaceutical companies to expand their research and development activities to develop new vaccines against the new coronavirus. Companies are conducting clinical trials to try to stop the spread of the COVID-19 virus. Pharmaceutical insulator suppliers to biopharmaceutical organizations have more opportunities as the number of clinical trials increases.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the pharmaceutical medical display market.

Recent Developments

• In June 2022, the company announced a partnership with Medical Supply Company (MSC) to market and service Jacomex equipment to the pharmaceutical and pharmaceutical industries in Ireland. MSC has many years of recognized expertise in the market with field teams closest to customers and company’s commercial team currently working abroad had the pleasure of welcoming Cian Murphy and finalizing the agreement between Jacomex and MSC. The beginning of a long and fruitful collaboration. This has helped the company to expand their business.
• In January 2022, Clario partnered with XingImaging, a radiopharmaceutical production and positron emission tomography (PET) acquisition company, to deliver PET imaging clinical trials for testing novel therapeutics in China. The partnership offers to share the joint resources and neuroscience experts of Clario and XingImaging to expedite the startup of clinical trials and drug discovery in China.

Asia-Pacific Pharmaceutical isolator market Scope

Asia-Pacific pharmaceutical isolator market is segmented into type, pressure, application, configuration, system type, end user and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

ASIA-PACIFIC PHARMACEUTICAL ISOLATOR MARKET, BY TYPE

• ASEPTIC ISOLATORS
• CONTAINMENT ISOLATORS
• BIO ISOLATORS
• SAMPLING AND WEIGHING ISOLATORS
• ACTIVE PHARMACEUTICAL INGREDIENT (API) MANUFACTURING ISOLATORS
• RADIOPHARMACEUTICAL ISOLATORS
• PRODUCTION ISOLATORS
• OTHERS

On the basis of type, the Asia-Pacific pharmaceutical isolator market is segmented into aseptic isolators, containment isolators, bio isolators, sampling and weighing isolators, active pharmaceutical ingredient (API) manufacturing isolators, radiopharmaceutical isolators, production isolators, others.

ASIA-PACIFIC PHARMACEUTICAL ISOLATOR MARKET, BY SYSTEM TYPE

• CLOSED SYSTEM
• OPEN SYSTEM

On the basis of system type, the Asia-Pacific pharmaceutical isolator market is segmented into closed system, open system.

ASIA-PACIFIC PHARMACEUTICAL ISOLATOR MARKET, BY PRESSURE

• POSITIVE PRESSURE
• NEGATIVE PRESSURE

On the basis of pressure, the Asia-Pacific pharmaceutical isolator market is segmented into positive pressure and negative pressure.

ASIA-PACIFIC PHARMACEUTICAL ISOLATOR MARKET, BY CONFIGURATION

• FLOOR STANDING
• MODULAR
• MOBILE
• COMPACT
• TABLE TOP
• PORTABLE
• OTHERS

On the basis of configuration, the Asia-Pacific pharmaceutical isolator market is segmented into floor standing, modular, mobile, compact, table top, portable, others.

ASIA-PACIFIC PHARMACEUTICAL ISOLATOR MARKET, BY APPLICATION

• STERILITY TESTING
• MANUFACTURING
• SAMPLING/ WEIGHING/ DISTRIBUTION
• MEDICAL DEVICE MANUFACTURING
• OTHERS

On the basis of application, the Asia-Pacific pharmaceutical isolator market is segmented into sterility testing, manufacturing, sampling/ weighing/ distribution, medical device manufacturing, others.

ASIA-PACIFIC PHARMACEUTICAL ISOLATOR MARKET, BY END USER

• HOSPITALS
• DIAGNOSTIC LABORATORIES
• ACADEMIC AND RESEARCH INSTITUTES
• PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES
• CONTRACT RESEARCH ORGANIZATIONS
• OTHERS

On the basis of end user, the Asia-Pacific pharmaceutical isolator market is segmented into hospitals, diagnostic laboratories, academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations, others.

ASIA-PACIFIC PHARMACEUTICAL ISOLATOR MARKET, BY DISTRIBUTION CHANNEL

• DIRECT TENDER
• RETAIL SALES
• THIRD PARTY DISTRIBUTORS

On the basis of distribution channel, the Asia-Pacific pharmaceutical isolator market is segmented into direct tender, retail sales, third party distributors.

Asia-Pacific Pharmaceutical Isolator Market Regional Analysis/Insights

The Asia-Pacific pharmaceutical isolator market is analyzed and market size information is provided type, pressure, application, configuration, system type, end user, and distribution channel.

The countries covered in this market report are China, Japan, India, South Korea, Singapore, Thailand, Malaysia, Australia, Philippines, Indonesia and rest of Asia-Pacific. In 2022, China is dominating due to increasing investments in R&D.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Asia-Pacific Pharmaceutical Isolator Market Share Analysis

Asia-Pacific pharmaceutical isolator market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Asia-Pacific pharmaceutical isolator market.

Some of the major players operating in the Asia-Pacific pharmaceutical isolator market are Getinge, SKAN AG, Hosokawa micron ltd, Gelman Singapore, Azbil Corporation, Germfree Laboratories, Inc., M. Braun Inertgas-Systeme Gmbh, Nuaire, Iteco S.R.L., Comecer S.P.A., Hecht Technologie Gmbh, Steriline S.R.L., Envair Limited, Tema Sinergie S.P.A, Schematic Engineering Industries, Chiyoda Corporation, Chamunda Pharma Machinery Pvt. Ltd, Bioquell (Ecolab Solution), Jacomex, Fedegari Autoclavi S.p.A., LAF Technologies, ISO Tech Design, Cytiva, Esco Pharma.

Research Methodology: Asia-Pacific Pharmaceutical Isolator Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Asia-Pacific vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.

SKU-35216